Methods and compositions for the attenuation and/or prevention of stress/catabolic responses

Abstract

Methods and compositions for treating metabolic stress are provided. The method comprises the steps of administering a therapeutically effective amount of conjugated linoleic acid.

1 . A method for preventing the onset of metabolic stress in an individual comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid.  
     
     
         2 . The method of  claim 1  wherein approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.  
     
     
         3 . The method of  claim 1  wherein the individual is preparing for surgery, or recently had surgery.  
     
     
         4 . The method of  claim 1  wherein the individual recently had an acute illness.  
     
     
         5 . The method of  claim 1  wherein the individual has a chronic illness.  
     
     
         6 . The method of  claim 1  wherein the conjugated linoleic acid is chosen from the group consisting of a pure isomer of octadecadienoic acid and a mixture of octadecadienoic acid isomers including: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9 trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.  
     
     
         7 . The method of  claim 1  wherein the composition includes a flavor.  
     
     
         8 . The method of  claim 1  wherein the composition includes an artificial sweetener.  
     
     
         9 . A method of reducing the treating of metabolic stress in an individual suffering from same comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid.  
     
     
         10 . The method of  claim 9  wherein approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.  
     
     
         11 . The method of  claim 9  wherein the individual is preparing for or recovering from invasive surgery.  
     
     
         12 . The method of  claim 9  wherein the individual has a chronic illness.  
     
     
         13 . The method of  claim 9  wherein the conjugated linoleic acid is chosen from the group consisting of a pure isomer of octadecadienoic acid and a mixture of octadecadienoic acid isomers including: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.  
     
     
         14 . The method of  claim 9  wherein the composition includes a flavor.  
     
     
         15 . The method of  claim 9  wherein the composition includes an artificial sweetener.  
     
     
         16 . A method of treating chronic obesity comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid  
     
     
         17 . The method of  claim 16  wherein approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.  
     
     
         18 . The method of  claim 16  wherein wherein the conjugated linoleic acid is chosen from the group consisting of a pure isomer of octadecadienoic acid and a mixture of octadecadienoic acid isomers including: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.  
     
     
         19 . A method of preventing or treating cachexia comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient having or at risk to have cachexia.  
     
     
         20 . A method of reducing the risk of mortality for a patient that will have or has had cardiac bypass surgery comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient that has had cardic bypass surgery.  
     
     
         21 . The method of  claim 20  wherein the composition is administered at any time prior to two years after the bypass surgery.